Nektar Therapeutics (NKTR) entered a quiet period beginning this month as it awaits the trial results for its lead drug candidate, Rezpegaldesleukin, in alopecia areata.
Rezpegaldesleukin, also known as Rezpeg, NKTR-358, or formerly LY3471851, is a pegylated recombinant human interleukin-2 (IL-2) therapeutic. This engineered biologic is a modified form of a naturally occurring protein that plays a key role in regulating immune system activity.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.